Facial Lipoatrophy

1. Silvers SL, et al Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg. 2006 Sep;118(3 Suppl):34S-45S

2. Comite, S.L., et al., Treatment of HIV-associated facial lipoatrophy with Radiance FN (Radiesse). Dermatol Online J, 2004. 10(2): p. 2.

Note: These studies were done with CaHA technology based dermal fillers which are relevant since RENÚ® is a substantially equivalent product and contain the same components in equivalent formulations.